Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.15429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Omar Afroz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Afroz, MBBS, MD Psychiatry, Senior Resident, Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, ORCID: 0009-0001-8…. Hauptthemen laut MEDLINE: Lorazepam, Interview, Psychological, Mental Disorders, Psychiatry. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Drug-assisted interviews have been used in psychiatry for about a century. The use of barbiturates for this purpose has declined, and the use of lorazepam has gained popularity over time for conducting drug-assisted interviews, given a better safety profile. However, the evidence for the use of lorazepam for drugassisted interviews is fragmented and anecdotal, and mostly in the form of case reports. The current review aims to synthesize available evidence on the use of lorazepam-assisted interviews in psychiatry.
Methods
For this narrative review, a literature search was conducted using PubMed, Scopus, and Google Scholar. Peer-reviewed articles on the use of lorazepam for drug-assisted interviews for psychiatric patients were identified, and data were manually extracted and synthesized.
Results
Eleven case reports and one case series on lorazepam-assisted interviews were identified. Dissociative disorder was the common diagnosis where it was used, with most studies reporting significant improvement after the interviews. Adverse events, though rare, included excessive sedation, disinhibition, agitation, and emotional lability. Interview protocols varied among the studies, with doses ranging from 2 to 18 mg, administered through intravenous routes either as boluses or infusion (rates ranging from 0.05 mg/min to 0.1 mg/min). Most studies involved single sessions, with a maximum of 12 sessions in one case report.
Conclusion
Lorazepam-assisted interview may hold potential clinical utility in appropriate cases. Future studies are needed to establish efficacy and safety and to evaluate interview protocols. Psychopharmacology Bulletin. 2026;56(1):98–111.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Afroz, MBBS, MD Psychiatry, Senior Resident, Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, ORCID: 0009-0001-8303-8260.
- Ramawat, MBBS, MD Psychiatry, Research Scientist II (Medical), National Drug Dependence Treatment Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, ORCID: 0000-0002-3719-3438.
- Saini, MBBS, MD Psychiatry, Assistant Professor, Department of Psychiatry, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGI), Lucknow, Uttar Pradesh, ORCID: 0000-0001-9553-2349.
- Sarkar, MBBS, MD Psychiatry, Additional Professor, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, ORCID: 0000-0002-3827-1549.
Zitieren
APA
Afroz, O., Ramawat, R. B., Saini, R., & Sarkar, S. (2026). Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15429
Vancouver
Afroz O, Ramawat RB, Saini R, Sarkar S. Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15429
BibTeX
@article{Afroz2026,
author = {Afroz, Omar and Ramawat, Raja Babu and Saini, Romil and Sarkar, Siddharth},
title = {Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.15429}
}
EUVIMED